Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194336 · ClinicalTrials.gov registry record
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
A clinical trial of Biomarkers, Pharmacological, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- 84
- Enrollment target
- 1
- Study location
NCT01194336: Completed study of Biomarkers, Pharmacological, sponsored by U.S. Army Medical Research and Development Command.
NCT01194336 is a study of Biomarkers, Pharmacological that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194336, a study of Biomarkers, Pharmacological, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.
Primary Outcome
The primary objective of this study is to determine whether huperzine A (a nutraceutical), donepezil (Aricept®), and galantamine (Razadyne®), impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Donepezil
- DRUG Galantamine
- DRUG Huperzine A
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-10 |
What the finished NCT01194336 record still lists
NCT01194336 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 1 condition, with Biomarkers, Pharmacological appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01194336 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01194336 about?
NCT01194336 is a clinical study titled "Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance". The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.
What is the current status of trial NCT01194336?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2012-02. Estimated completion is 2012-10.
What conditions does trial NCT01194336 study?
This clinical trial studies the following conditions: Biomarkers, Pharmacological.
What interventions are being tested in trial NCT01194336?
The interventions under investigation include: Placebo (OTHER), Donepezil (DRUG), Galantamine (DRUG), Huperzine A (DRUG).
Who is sponsoring clinical trial NCT01194336?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01194336 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia